Around 5% of US Population Diagnosed With Autoimmune DiseaseJanuary 14, 2025Rare DiseasesMultiple SclerosisMyasthenia Gravis
Myasthenia Gravis: Where Does Traditional Therapy Fit In?November 6, 2024Myasthenia GravisRare DiseasesNeuromuscular Disorders
Neurologists Lack Awareness of Steroid ToxicityOctober 28, 2024Neuromuscular DisordersMyasthenia GravisRare Diseases
Digital Tool May Help Neurologists Assess Steroid ToxicityOctober 28, 2024Myasthenia GravisNeuromuscular DisordersRare Diseases
Pediatric Myasthenia Gravis: Don’t Treat Children Like AdultsOctober 22, 2024Myasthenia GravisNeuromuscular DisordersPediatricsRare Diseases
Myasthenia Gravis: Similar Symptoms in Relatives Raise Question of GenesOctober 18, 2024Myasthenia GravisNeuromuscular DisordersRare Diseases
Sustained Control with Investigational Monoclonal Antibody for Myasthenia GravisOctober 17, 2024Myasthenia GravisNeuromuscular DisordersRare Diseases
First-in-Class B-Cell Depleting Agent Promising for Myasthenia GravisOctober 17, 2024Myasthenia GravisNeuromuscular DisordersRare Diseases
Myasthenia Gravis: Patient Choice, Cultural ChangeSeptember 30, 2024Rare DiseasesMyasthenia GravisNeuromuscular Disorders
Autoimmune Disease Risk May Rise Following Cushing Disease Remission After SurgeryFebruary 22, 2024Multiple SclerosisMyasthenia GravisNeurosurgery & Trauma
Novel myasthenia gravis therapies bring opportunities, challengesNovember 21, 2023Myasthenia GravisRare DiseasesNeuromuscular Disorders
Newly approved myasthenia gravis drug shows sustained benefits in early respondersNovember 15, 2023Myasthenia GravisRare DiseasesNeuromuscular Disorders
U.S. study finds unexpectedly high prevalence of myasthenia gravisNovember 8, 2023Myasthenia GravisNeuromuscular DisordersRare Diseases
In myasthenia gravis, antibodies pass open-label testsNovember 3, 2023Myasthenia GravisNeuromuscular DisordersRare DiseasesPediatrics
Myasthenia gravis drug gets FDA nodJune 27, 2023Myasthenia GravisRare DiseasesNeuromuscular Disorders
